Show simple item record

dc.contributor.authorLoyse, A*
dc.contributor.authorBurry, J*
dc.contributor.authorCohn, J*
dc.contributor.authorFord, N*
dc.contributor.authorChiller, T*
dc.contributor.authorRibeiro, I*
dc.contributor.authorKoulla-Shiro, S*
dc.contributor.authorMghamba, J*
dc.contributor.authorRamadhani, A*
dc.contributor.authorNyirenda, R*
dc.contributor.authorAliyu, SH*
dc.contributor.authorWilson, D*
dc.contributor.authorLe, T*
dc.contributor.authorOladele, R*
dc.contributor.authorLesikari, S*
dc.contributor.authorMuzoora, C*
dc.contributor.authorKalata, N*
dc.contributor.authorTemfack, E*
dc.contributor.authorMapoure, Y*
dc.contributor.authorSini, V*
dc.contributor.authorChanda, D*
dc.contributor.authorShimwela, M*
dc.contributor.authorLakhi, S*
dc.contributor.authorNgoma, J*
dc.contributor.authorGondwe-Chunda, L*
dc.contributor.authorPerfect, C*
dc.contributor.authorShroufi, A*
dc.contributor.authorAndrieux-Meyer, I*
dc.contributor.authorChan, A*
dc.contributor.authorSchutz, C*
dc.contributor.authorHosseinipour, M*
dc.contributor.authorVan der Horst, C*
dc.contributor.authorKlausner, JD*
dc.contributor.authorBoulware, DR*
dc.contributor.authorHeyderman, R*
dc.contributor.authorLalloo, D*
dc.contributor.authorDay, J*
dc.contributor.authorJarvis, JN*
dc.contributor.authorRodrigues, M*
dc.contributor.authorJaffar, S*
dc.contributor.authorDenning, D*
dc.contributor.authorMigone, C*
dc.contributor.authorDoherty, M*
dc.contributor.authorLortholary, O*
dc.contributor.authorDromer, F*
dc.contributor.authorStack, M*
dc.contributor.authorMolloy, SF*
dc.contributor.authorBicanic, T*
dc.contributor.authorvan Oosterhout, J*
dc.contributor.authorMwaba, P*
dc.contributor.authorKanyama, C*
dc.contributor.authorKouanfack, C*
dc.contributor.authorMfinanga, S*
dc.contributor.authorGovender, N*
dc.contributor.authorHarrison, TS*
dc.date.accessioned2018-12-17T18:13:18Z
dc.date.available2018-12-17T18:13:18Z
dc.date.issued2018-10-18
dc.date.submitted2018-12-13
dc.identifier.citationLeave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. 2018 Lancet Infect Disen
dc.identifier.issn1474-4457
dc.identifier.pmid30344084
dc.identifier.doi10.1016/S1473-3099(18)30493-6
dc.identifier.urihttp://hdl.handle.net/10144/619321
dc.description.abstractIn 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine. In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95% CI -29 to 41). However, with widely used fluconazole monotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many African LMIC settings. Therefore, the potential to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is substantial. Sustainable access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of this Personal View.
dc.language.isoenen
dc.publisherThe Lanceten
dc.rightsArchived with thanks to The Lancet. Infectious Diseasesen
dc.titleLeave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countriesen
dc.identifier.journalThe Lancet. Infectious Diseasesen
refterms.dateFOA2019-03-04T14:17:08Z
html.description.abstractIn 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine. In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95% CI -29 to 41). However, with widely used fluconazole monotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many African LMIC settings. Therefore, the potential to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is substantial. Sustainable access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of this Personal View.


Files in this item

Thumbnail
Name:
Loyse et al - 2018 - Leave no ...
Size:
750.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record